Muse cells and iPSCs are both pluripotent, but Muse cells occur naturally in the body and don’t require genetic reprogramming or carry tumor risk, while iPSCs are built in a lab from adult cells and come with a real risk of forming teratomas.

This guide breaks down the biology, the clinical trial data behind each, and what the difference actually means if you’re weighing regenerative treatment options.

If you’ve spent any time researching regenerative medicine, you’ve probably run into two terms that sound like they belong in the same sentence: Muse cells and iPSCs.

Some clinics use the words almost interchangeably.

Others treat them like rivals in a safety debate.

Neither framing tells you what you actually need to know.

The real difference between Muse cells and iPSCs comes down to where each one comes from, and what that origin does to its safety profile.

Muse cells already exist in your body.

iPSCs have to be built in a lab from your own cells, and that construction process changes how they behave once they’re transplanted.

That distinction affects tumor risk, how long a treatment takes to prepare, and whether a donor product needs to match your immune system.

Here’s what actually separates the two, backed by the clinical data behind each one.

What Are Muse Cells?

Muse cells, short for multilineage-differentiating stress-enduring cells, are naturally occurring stem cells found in bone marrow, peripheral blood, and connective tissue throughout the body.

Discovered in 2010 by a research team led by Dr. Mari Dezawa, they’re one of the only pluripotent cell types the human body makes on its own, with no genetic engineering or lab reprogramming involved.

Researchers first identified Muse cells because a small population of adult cells survived conditions that kill off everything else nearby: long-term serum starvation, extreme low oxygen, and other severe stress.

That survival trait is where the name comes from.

What makes them identifiable is a specific marker combination.

Muse cells test positive for both SSEA-3, a marker usually associated with embryonic pluripotency, and CD105, a mesenchymal marker, a pairing that doesn’t show up in ordinary adult stem cells.

Even so, they’re rare: roughly 1 out of every 3,000 cells in fresh bone marrow qualifies as a true Muse cell.

Muse cells also aren’t a cell type you’d find floating on their own.

They exist as a small subpopulation inside mesenchymal stem cell (MSC) preparations, which is part of why Muse cells and standard MSCs get confused for each other even though they behave very differently once they reach damaged tissue.

The name “Dezawa Muse cells” also gets used loosely across the industry, and it doesn’t always mean what patients assume it means. 

The original scientific discovery and the commercial products marketed under similar names aren’t automatically the same thing, which is worth understanding before evaluating any specific treatment.

What Are iPSCs?

Induced pluripotent stem cells, or iPSCs, are adult cells, usually taken from skin or blood, that scientists reprogram in a lab to behave like embryonic stem cells.

The process uses a small set of reprogramming factors to reset the cell’s identity, giving it the ability to become almost any cell type in the body.

The technique was developed in 2006, when researchers found they could take a mature, already-specialized cell and push it backward into an embryonic-like state.

The result behaves like a stem cell that was never differentiated in the first place, which is genuinely useful for research.

That reprogramming is powerful, but it’s also the source of iPSCs’ biggest limitation.

Resetting an adult cell’s identity takes real time in the lab. 

Differentiating iPSCs into a specific, usable cell type typically requires weeks to months of cytokine or gene-dependent processing before a batch is ready, and every batch needs careful screening for leftover cells that didn’t finish differentiating.

What Is the Core Difference Between Muse Cells and iPSCs?

The core difference is origin and risk.

Muse cells are pluripotent stem cells your body already makes, so they don’t need genetic reprogramming and they don’t form tumors after transplant.

iPSCs are artificially reprogrammed from adult cells, which makes them powerful research tools but also gives them a real risk of forming teratomas if any reprogrammed cells remain undifferentiated at the time of transplant.

Origin: Naturally Occurring vs. Lab-Reprogrammed

Muse cells already exist inside you, sitting in bone marrow, peripheral blood, and connective tissue until a stress signal activates them.

Nobody manufactures them from scratch.

iPSCs don’t exist until a lab creates them.

Technicians take a sample of skin or blood cells and use reprogramming factors to push those mature cells back into a pluripotent state.

That’s an engineered product, not a cell type the body produces on its own.

Tumor Risk: Teratomas vs. No Reported Tumorigenicity

This is the difference that matters most to patients.

iPSCs retain an almost unlimited capacity to proliferate, and that same trait that makes them so useful for research is also what allows leftover undifferentiated cells to form teratomas after transplant.

Muse cells don’t carry that risk.

They’re non-tumorigenic largely because they already exist naturally in the body rather than being pushed into pluripotency through artificial reprogramming.

No published trial has reported teratoma formation from Muse cell transplantation.

Preparation Time: Days to Weeks vs. Months

Because Muse cells are collected rather than reprogrammed, a usable product can be ready in days to weeks.

There’s no multi-week reprogramming phase to wait through.

iPSCs need that reprogramming window plus a separate characterization phase to confirm the cells differentiated correctly and didn’t retain tumor-forming potential.

That combined process commonly runs into weeks or months before a batch is ready, which is one reason iPSC-based treatments remain mostly confined to research rather than routine clinical use.

Immune Compatibility: Natural Privilege vs. HLA Matching

Muse cells express HLA-G, a molecule associated with immune tolerance, which lets donor Muse cells survive in a recipient’s body for an extended period without immunosuppressant drugs or HLA matching.

That’s a major practical advantage for a treatment meant to be available off the shelf.

iPSCs don’t have that built-in advantage.

Unless they’re created from the patient’s own cells, which adds time and cost, or matched carefully to the recipient’s immune profile, the body is more likely to reject them.

Why Don’t Muse Cells Form Tumors Like iPSCs Do?

Muse cells avoid tumor formation because of how they maintain pluripotency at the molecular level.

They rely on a tumor-suppressing pathway built around the microRNA let-7, while iPSCs depend on the tumor-promoting gene Lin28 to stay pluripotent, a mechanism that leaves the door open for uncontrolled growth.

Pluripotency itself isn’t the problem.

Both cell types can become almost any tissue in the body, and that flexibility is the whole point of using them in regenerative medicine.

The difference is which molecular switch keeps that flexibility turned on.

Muse cells maintain pluripotency through let-7, a microRNA known for suppressing tumor growth, while iPSCs rely on Lin28, a gene linked to driving cell proliferation.

That single difference in molecular wiring helps explain why one cell type stays under control after transplant and the other doesn’t always.

Muse cells also don’t proliferate indefinitely the way iPSCs can.

Once injected, a Muse cell senses a damage signal called sphingosine-1-phosphate and migrates directly to the injury site, then differentiates in place instead of continuing to divide.

What Does the Clinical Evidence Actually Show?

Biology explains why Muse cells should be safer.

Clinical trials are what actually confirm it.

In a double-blind, placebo-controlled stroke trial, patients who received a Muse cell product called CL2020 showed meaningful functional improvement 40% of the time, compared to 10% in the placebo group, measured on the modified Rankin Scale 12 weeks after treatment.

Japan’s health ministry found the safety and efficacy data strong enough to grant CL2020 conditional approval for ischemic stroke in 2022.

Heart attack patients showed a similar signal.

In a small trial of three patients with ST-elevation myocardial infarction, left ventricular ejection fraction improved from an average of 40.7% to 52.0% over 12 weeks after a single Muse cell infusion, with no immunosuppressant support needed.

The SHIELD trial tested Muse cells in a far more vulnerable population: newborns with hypoxic-ischemic encephalopathy.

All nine infants survived, 89% reached a favorable motor function score compared to 77% in the national registry, and only one mild, self-resolving side effect was reported across the entire study.

Additional trials in ALS, spinal cord injury, and epidermolysis bullosa have reported similar safety patterns.

None of these studies are large by pharmaceutical standards, and the researchers behind them are candid that bigger, randomized trials are still needed to confirm efficacy.

But across every published trial so far, the safety signal has held: no teratomas, no uncontrolled growth, no need for aggressive immune suppression.

Are Muse Cells Always the Better Choice?

Not necessarily.

Muse cells have a stronger safety profile for direct patient treatment, but iPSCs still have real advantages in research, including unlimited expansion for drug testing and the ability to model a specific patient’s disease in a dish.

Muse cells are better suited to the clinic today.

iPSCs remain more useful in the lab.

It’s worth being honest about the limitations on both sides.

Muse cells are naturally rare, which makes large-scale isolation and manufacturing harder than simply growing a cell line indefinitely in a dish, the way researchers can with iPSCs.

That rarity is part of why product quality varies so much between providers.

It’s also why verifying exactly what you’re being offered matters before committing to any Muse cell treatment.

Not every clinic marketing Muse cell therapy is using a product that meets the same isolation and purity standards.

iPSCs, meanwhile, remain genuinely valuable, just not primarily as a direct patient treatment yet.

The unlimited proliferation that creates tumor risk in a transplant is exactly what makes iPSCs useful for growing large quantities of cells to study a disease or test new drugs in a lab.

That’s a different job than the one Muse cells are being used for in clinics today.

How Cellular Hope Institute Approaches Muse Cell Therapy

At Cellular Hope Institute, the medical team treats this distinction as the starting point for a patient conversation, not a marketing angle.

Because Muse cells carry a different risk profile than iPSCs or standard MSCs, each patient’s history and condition get reviewed before Muse cell therapy is recommended as part of a treatment plan.

The clinic’s Muse cell therapy program is built around sourcing verified product and working with physicians in Cancún, Mexico who track the same clinical literature covered above.

Patients considering treatment can review what the procedure actually involves, from screening to infusion to follow-up before deciding whether it fits their situation.

This isn’t presented as a guaranteed cure.

It’s an option grounded in the trial data above, offered to patients who want a cell therapy with a safety profile that’s been tested in real clinical settings rather than only in a lab.

Muse cells and iPSCs both start from the same idea: an adult-derived cell that can become many other cell types.

One occurs naturally and stays under control once it’s back in the body.

The other is built in a lab and carries a real tumor risk until it’s fully differentiated.

That difference is a big part of why Muse cells have moved further into real clinical use while iPSCs remain more valuable in research than in the clinic.

If you’re weighing regenerative treatment options and want to know whether Muse cell therapy fits your condition, Cellular Hope Institute’s team can walk through your history, the current clinical evidence, and what realistic outcomes look like before you decide on anything.

FAQs: What Is the Difference Between Muse Cells and iPSCs

Are Muse cells the same thing as iPSCs?

No. Muse cells are pluripotent stem cells that already exist in your body, while iPSCs are adult cells artificially reprogrammed in a lab to become pluripotent. Both can become many cell types, but they differ in origin, safety profile, and how long they take to prepare for treatment.

Are Muse cells actually safer than iPSCs in practice?

Based on published clinical trials so far, yes. No trial using Muse cells has reported teratoma formation or serious cell-related adverse events, while iPSCs carry a documented tumor risk tied to leftover undifferentiated cells. Muse cell trials remain relatively small, so larger studies are still needed to confirm long-term safety at scale.

Can iPSCs be used to treat patients today?

iPSCs are used far more often in research, drug testing, and disease modeling than in direct patient treatment. Their tumor risk and lengthy reprogramming process make them harder to use safely in a clinical setting compared to Muse cells, which don’t require that reprogramming step.

How much does Muse cell therapy cost?

Cost varies based on the condition being treated, the dose required, and where treatment takes place. For patients considering treatment, a full breakdown of what affects Muse cell therapy pricing in Mexico is worth reviewing before scheduling a consultation.

How do I know if a clinic is using real Muse cells?

True Muse cells are isolated under specific stress conditions and verified through markers like SSEA-3 and CD105. Because the term gets used loosely across the industry, it’s worth asking any clinic directly how their product is isolated and verified before you start treatment.